Join our Free Newsletter and unlock 50% off AltIndexFree newsletter + 50% offJoin free
11,000194.9%
Est. monthly webpage visitors. Updated Sep 15, 2026
Loading...

Foghorn Therapeutics Monthly Web Traffic

Foghorn Therapeutics’s website receives an estimated 11,000 monthly visits, roughly flat (+0.0%) over the past three months.

At 11,000 monthly visits, Foghorn Therapeutics trails industry peers like Amgen (601,000) and Gilead Sciences (495,000).

How Web Traffic Impacts FHTX’s AI Score

Web traffic is a real-time read on consumer demand and brand engagement: for consumer-facing companies, a sustained change in website visits can precede changes in reported revenue. AltIndex feeds Foghorn Therapeutics’s monthly visit estimates into the FHTX AI Score as one of 25+ alternative data signals, where traffic momentum is weighed against hiring, sentiment, and fundamentals.

For other growth metrics, see Foghorn Therapeutics app downloads, Google Trends, Instagram followers, and LinkedIn headcount.

Foghorn Therapeutics Web Traffic: Frequently Asked Questions

Foghorn Therapeutics's website receives approximately 11,000 monthly visits, based on AltIndex's estimate aggregated from the top web traffic data providers. This figure includes desktop and mobile visitors to the company's primary domain.

Foghorn Therapeutics's web traffic has been roughly flat (+0.0%) over the past three months.

Web traffic is a real-time indicator of consumer demand and brand engagement. For consumer-facing companies, declining website visits can precede revenue slowdowns. AltIndex tracks web traffic as one of 25+ signals in its AI Score model.

No single data point predicts a stock price on its own, but website traffic is a leading indicator: a sustained shift in Foghorn Therapeutics's monthly visitors can show up before it reaches reported revenue. That is why AltIndex combines FHTX's web traffic trend with hiring, sentiment, app downloads, and 20+ other signals in its AI Score rather than reading any one signal in isolation.

Foghorn Therapeutics underperforms its industry peers when it comes to Webpage traffic, ranking dead last.

Sign up and get more insights on Foghorn Therapeutics and its Webpage performance.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.